Holding in Company
12 February 2021
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has been advised that, following a share purchase on 11 February 2021, Paul Warwick holds 814,080 ordinary shares in the Company, representing 3.2 per cent. of the Company’s issued share capital.
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com | |
| Dr Paul Kerr, Chief Executive Officer | Via Walbrook PR | |
| James Fair, Chief Financial Officer | ||
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
| James Reeve / Asha Chotai (Corporate Finance) | ||
| Tony Quirke (Sales and Corporate Broking) | ||
| Walbrook PR | Tel: +44 (0)20 7933 8780 fusion@walbrookpr.com | |
| Anna Dunphy | Mob: +44 (0)7876 741 001 | |
| Paul McManus | Mob: +44 (0)7980 541 893 | |
About Fusion Antibodies plc
Fusion is a Belfast based biotechnology company providing a range of
antibody engineering services for the development of antibodies for both
therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18
December 2017. Fusion provides a broad range of services in antibody
generation, development, production, characterisation and optimisation.
These services include antigen expression, antibody production,
purification and sequencing, antibody humanisation using Fusion's
proprietary CDRxTM platform and the production of
antibody generating stable cell lines to provide material for use in
clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 200
humanisation projects for its international, blue-chip client base,
which has included eight of the top 10 global pharmaceutical companies
by revenue.
Fusion is a Collaborative Research Organisation (CRO) which provides
antibody discovery, engineering and supply, through to cell line
development. At every stage, our client's vision is central to how we
work, ensuring the best molecule goes to the clinic. Our world-class
humanization and antibody optimization platforms harness the power of
the natural diversity of antibodies. To address remaining market needs
in antibody discovery, Fusion is creating a fully human antibody library
to capture the entire human antibody repertoire.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster and ultimately speed up the drug development process.
The global monoclonal antibody therapeutics market was valued at $95.5 billion in 2017 and is forecast to surpass $174.2 billion in 2026, an increase at a CAGR of 6.9 per cent. for the period 2018 to 2026. In 2018, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $62 billion.